These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27175591)

  • 1. Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells.
    Brasseur K; Fabi F; Adam P; Parent S; Lessard L; Asselin E
    Oncotarget; 2016 Jun; 7(24):36971-36987. PubMed ID: 27175591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation.
    Chaudhry P; Singh M; Parent S; Asselin E
    Mol Cell Biol; 2012 Feb; 32(4):826-39. PubMed ID: 22184067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional regulation of pro-apoptotic Par-4 by NF-kappaB/p65 and its function in controlling cell kinetics during early events in endometrial tumourigenesis.
    Saegusa M; Hashimura M; Kuwata T; Okayasu I
    J Pathol; 2010 May; 221(1):26-36. PubMed ID: 20186924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells.
    Saydmohammed M; Joseph D; Syed V
    J Cell Biochem; 2010 May; 110(2):447-56. PubMed ID: 20235152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition.
    Chaudhry P; Fabi F; Singh M; Parent S; Leblanc V; Asselin E
    Cell Death Dis; 2014 Feb; 5(2):e1044. PubMed ID: 24503536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.
    Moreno-Bueno G; Fernandez-Marcos PJ; Collado M; Tendero MJ; Rodriguez-Pinilla SM; Garcia-Cao I; Hardisson D; Diaz-Meco MT; Moscat J; Serrano M; Palacios J
    Cancer Res; 2007 Mar; 67(5):1927-34. PubMed ID: 17332319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PAR-4 in ovarian cancer.
    Meynier S; Kramer M; Ribaux P; Tille JC; Delie F; Petignat P; Cohen M
    Oncotarget; 2015 Sep; 6(26):22641-52. PubMed ID: 26246468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species.
    Nguyen H; Syed V
    Gynecol Endocrinol; 2011 Oct; 27(10):830-6. PubMed ID: 21171931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
    Woo MG; Xue K; Liu J; McBride H; Tsang BK
    J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of icb-1 gene is interferon-gamma inducible in breast and ovarian cancer cell lines and affects the IFN gamma-response of SK-OV-3 ovarian cancer cells.
    Treeck O; Kindzorra I; Pauser K; Treeck L; Ortmann O
    Cytokine; 2005 Nov; 32(3-4):137-42. PubMed ID: 16219472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspase-8-mediated PAR-4 cleavage is required for TNFα-induced apoptosis.
    Treude F; Kappes F; Fahrenkamp D; Müller-Newen G; Dajas-Bailador F; Krämer OH; Lüscher B; Hartkamp J
    Oncotarget; 2014 May; 5(10):2988-98. PubMed ID: 24931006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
    Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
    Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy-independent enhancing effects of Beclin 1 on cytotoxicity of ovarian cancer cells mediated by proteasome inhibitors.
    Liu C; Yan X; Wang HQ; Gao YY; Liu J; Hu Z; Liu D; Gao J; Lin B
    BMC Cancer; 2012 Dec; 12():622. PubMed ID: 23270461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Analysis of the cl-Par-4 Tumor Suppressor as a Function of Ionic Environment.
    Raut KK; Ponniah K; Pascal SM
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33807852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of protease activated receptor-2 related to angiogenesis in tumor advancement of uterine endometrial cancers.
    Jahan I; Fujimoto J; Alam SM; Sato E; Sakaguchi H; Tamaya T
    Oncol Rep; 2007 Feb; 17(2):345-50. PubMed ID: 17203172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetramer formation by the caspase-activated fragment of the Par-4 tumor suppressor.
    Clark AM; Ponniah K; Warden MS; Raitt EM; Smith BG; Pascal SM
    FEBS J; 2019 Oct; 286(20):4060-4073. PubMed ID: 31177609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
    Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoresistance and targeted therapies in ovarian and endometrial cancers.
    Brasseur K; Gévry N; Asselin E
    Oncotarget; 2017 Jan; 8(3):4008-4042. PubMed ID: 28008141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.